BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

...able to ride the wave.Preclinical portfolio company Akouos Inc....
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...CureVac N.V. (NASDAQ:CVAC), succeeds Alison Lawton, who has stepped down for personal reasons. Precision medicine company Akouos Inc....
...Richard Makara, Cara’s VP, head of accounting and comptroller, had been interim CFO. BC Staff Arcus Biosciences Inc. Akouos Inc. AZTherapies...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...somewhat smaller than those of other gene therapy companies that have gone public in 2020. Akouos Inc....
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

...operations at Qpex Biopharma Inc.; Savage was senior medical director at Magenta Therapeutics Inc. (NASDAQ:MGTA). Akouos Inc....
...NSE:GLENMARK; BSE:532296) and Sangamo Therapeutics Inc. (NASDAQ:SGMO). Robin Sawka, BioCentury Staff Blackstone Group Ribometrix Inc. Dyne Therapeutics Inc. Mission Therapeutics Ltd. Akouos Inc. Annexon...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...VaxCyte Inc. (NASDAQ:PCVX), synthetic lethality company Repare Therapeutics Inc. (NASDAQ:RPTX), hearing loss gene therapy play Akouos Inc....
BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

...in recent weeks (see “Gan & Lee Hits Ceiling in First Day on Shanghai” ; “Akouos...
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...Among a trio of companies making their NASDAQ debuts on Friday, Akouos’ first-day rise of 29%...
...in the U.S. (see “More Biotechs Line Up” ). Preclinical hearing loss gene therapy company Akouos Inc....
...it had upsized its proposal earlier in the week from 8.3 million shares at $14-$16. Akouos’...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...iTeos Therapeutics S.A., are revisiting their IPO plans after snagging mezzanine rounds. Another pair -- Akouos Inc....
...ADORA2A activity in the presence of high adenosine concentrations. Ahead of their expected pricings Thursday, Akouos...
...of shares they expect to sell to 12.5 million (see “Trio Prepare for IPOs” ). Akouos...
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...ISE:AYP) proposed to list and raise follow-on money on the exchange. Fusion Pharmaceuticals Inc. and Akouos Inc....
...which is selling 8.4 million shares, would be valued at $562.7 million at the midpoint. Akouos...
...Targets WNT - Wingless-type MMTV integration site family Elizabeth S. Eaton, Staff Writer Illumina Inc. Fusion Pharmaceuticals Inc. Akouos Inc. PolyPid...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

...five companies seeking a listing on NASDAQ. Four filed to raise up to $100 million: Akouos Inc....
...and the Shanghai STAR board. Elizabeth S. Eaton, Staff Writer Generation Bio Co. Arya Sciences Acquisition Corp. Lantern Pharma Inc. Akouos Inc. Fusion...
Items per page:
1 - 10 of 22
BioCentury | Oct 17, 2020
Finance

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

...able to ride the wave.Preclinical portfolio company Akouos Inc....
BioCentury | Oct 2, 2020
Management Tracks

Merck’s Perlmutter joins insitro’s board; plus moves at PureTech, Intra-Cellular, Arcus and more

...CureVac N.V. (NASDAQ:CVAC), succeeds Alison Lawton, who has stepped down for personal reasons. Precision medicine company Akouos Inc....
...Richard Makara, Cara’s VP, head of accounting and comptroller, had been interim CFO. BC Staff Arcus Biosciences Inc. Akouos Inc. AZTherapies...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

...somewhat smaller than those of other gene therapy companies that have gone public in 2020. Akouos Inc....
BioCentury | Aug 6, 2020
Management Tracks

Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

...operations at Qpex Biopharma Inc.; Savage was senior medical director at Magenta Therapeutics Inc. (NASDAQ:MGTA). Akouos Inc....
...NSE:GLENMARK; BSE:532296) and Sangamo Therapeutics Inc. (NASDAQ:SGMO). Robin Sawka, BioCentury Staff Blackstone Group Ribometrix Inc. Dyne Therapeutics Inc. Mission Therapeutics Ltd. Akouos Inc. Annexon...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...VaxCyte Inc. (NASDAQ:PCVX), synthetic lethality company Repare Therapeutics Inc. (NASDAQ:RPTX), hearing loss gene therapy play Akouos Inc....
BioCentury | Jul 2, 2020
Finance

SK becomes Korea’s third-largest public healthcare company after $800M IPO

...in recent weeks (see “Gan & Lee Hits Ceiling in First Day on Shanghai” ; “Akouos...
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...Among a trio of companies making their NASDAQ debuts on Friday, Akouos’ first-day rise of 29%...
...in the U.S. (see “More Biotechs Line Up” ). Preclinical hearing loss gene therapy company Akouos Inc....
...it had upsized its proposal earlier in the week from 8.3 million shares at $14-$16. Akouos’...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...iTeos Therapeutics S.A., are revisiting their IPO plans after snagging mezzanine rounds. Another pair -- Akouos Inc....
...ADORA2A activity in the presence of high adenosine concentrations. Ahead of their expected pricings Thursday, Akouos...
...of shares they expect to sell to 12.5 million (see “Trio Prepare for IPOs” ). Akouos...
BioCentury | Jun 24, 2020
Finance

June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara

...ISE:AYP) proposed to list and raise follow-on money on the exchange. Fusion Pharmaceuticals Inc. and Akouos Inc....
...which is selling 8.4 million shares, would be valued at $562.7 million at the midpoint. Akouos...
...Targets WNT - Wingless-type MMTV integration site family Elizabeth S. Eaton, Staff Writer Illumina Inc. Fusion Pharmaceuticals Inc. Akouos Inc. PolyPid...
BioCentury | Jun 9, 2020
Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

...five companies seeking a listing on NASDAQ. Four filed to raise up to $100 million: Akouos Inc....
...and the Shanghai STAR board. Elizabeth S. Eaton, Staff Writer Generation Bio Co. Arya Sciences Acquisition Corp. Lantern Pharma Inc. Akouos Inc. Fusion...
Items per page:
1 - 10 of 22